Please provide your email address to receive an email when new articles are posted on . Crexont was associated with about a half an hour more of “good on” time per day compared with immediate release ...
Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently living ...
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily“Good On” time, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results